NDC 0002-6885Prescription (Rx only)FDA EMERGENCY USE AUTHORIZATION

Baricitinib

Active substance: Baricitinib

FDA labeler: Eli Lilly and Company

1 formulations • 1 package configurations
All 2 registered NDCs — click to copy
In one line

Baricitinib (Baricitinib) NDC 0002-6885 converts to 00002-6885-30 for billing. It is dispensed by a pharmacy and billed directly on the NDC — no HCPCS J-code is required.

openFDA Live Registry SyncHIPAA 5-4-2 StandardCMS Level II Crosswalk
Listing: 0002-6885
Billing & reimbursement crosswalk

NDC • HCPCS Level II • CPT administration

Reimbursement channel
NDC direct
Oral / Topical formulation billed directly via 11-Digit NDC (No HCPCS J-Code required).
Standard pharmacy claim — no J-Code required
11-digit HIPAA NDC
00002-6885-30
Zero-padded 5-4-2 format
Standard conversion
CPT administration code
Self-Administered (Oral)
Dispensed via retail/mail pharmacy. No clinical administration procedure (CPT) required.
UB-04 revenue code
Rev 0250
0250 (General Pharmacy)
Qualifier: UN
Complete drug registry

All registered strengths & packaging

Every registered strength and package for Baricitinib, with 10-digit and 11-digit NDC formats
Formulation / rolePackage NDCProduct NDC11-digit HIPAAPackaging detailCopy
4 mg/10002-6885-300002-688500002-6885-3030 TABLET, FILM COATED in 1 BOTTLE (0002-6885-30)
FDA drug label

Prescribing information

No Structured Product Labeling submission was returned for this listing, so the sections below are derived from its FDA registration record rather than the manufacturer's label.

6 Label Sections
Baricitinib is indicated for clinical therapeutic management as active pharmaceutical therapy containing BARICITINIB (4 mg/1).
Dosage must be individualized based on clinical therapeutic goals, route of administration (ORAL), and patient response. Refer to licensed physician prescribing guidelines.
Supplied as TABLET, FILM COATED. Active ingredients: BARICITINIB (4 mg/1).
Contraindicated in patients with severe hypersensitivity to baricitinib or formulation components.
Review complete patient medical history, potential contraindications, and drug-drug interactions prior to initiation.
Supplied under FDA Labeler: Eli Lilly and Company. Store according to manufacturer packaging specifications at controlled room temperature or refrigerated conditions as marked on commercial carton.
Labeler

Eli Lilly and Company

Full NDC portfolio, brand list and J-code coverage for this manufacturer.

Open the labeler
Pharmacologic class

Janus Kinase Inhibitor

Every other National Drug Code registered in the same established class.

Browse the class
Terms used here11-digit NDCPackage NDCN4 qualifier
Search more NDCs & medical codes